FDA warns Wild Arabic Herbs that its website sells Edral-17t as an unapproved drug for prostate and testicular cancers.
What happened
FDA reviewed the company’s website in May 2026 and found product labeling for “Edral-17t” claiming it treats prostate cancer, testicular malignancies, and other cancers. FDA said these claims make the product a drug and that it is a new drug without an approved application.
What FDA found
FDA says the website claims make Edral-17t a drug intended to treat disease.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says Edral-17t is a new drug—one not generally recognized as safe and effective—and has no FDA-approved application.
FD&C Act sections 201(p) and 505(a), 21 U.S.C. 321(p) and 355(a)FDA says selling or shipping this unapproved drug across state lines violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA tells the company to respond in writing within 15 business days to FDAAdvisory@fda.hhs.gov with the steps taken to correct the violations, steps to prevent recurrence, and supporting documents, using reference number 729192.
Who should pay attention
- sellers of herbal or supplement products with disease claims
- online platforms hosting product health claims
- consumers considering herbal cancer treatments
This is a summary. Read the original letter on fda.gov.